Welcome!

News Feed Item

Milestone Scientific Reports Fourth Quarter and 2013 Financial Results

Revenue Increases 15.8% to $10.0 Million in 2013; Domestic Instrument Sales Increase 44.8%; Achieves Net Income of $1.5 Million in 2013; Shareholders' Equity Increases to $5.5 Million at the End of Fiscal 2013 Compared to $1.9 Million at the End

LIVINGSTON, NJ--(Marketwired - March 12, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a leading medical research and development company that designs and patents innovative injection technology, today announced financial results for the fourth quarter and year ended December 31, 2013.

2013 Operating Highlights:

  • Formed a strategic partnership with Tri-anim Health Services Inc., a division of Sarnova Inc., one of the nation's largest specialty distributors of healthcare products, to distribute Milestone Medical's epidural instrument
  • Listed Milestone Medical subsidiary on the Warsaw Stock Exchange and raised $3 million from European investors
  • Implemented the use of the Wand® STA instrument in additional college and university dental hygienist programs

Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "We are pleased to report positive financial results for the year ended December 31, 2013. We continue to see top and bottom line growth, with revenue increasing 15.8% to $10.0 million and net income increasing to $1.5 million for 2013, compared to a net loss of approximately ($870,306) in 2012. Notably, we achieved a 44.8% increase in domestic instrument sales to $1.2 million in 2013. At the same time, our balance sheet continues to improve as we increased shareholders' equity to $5.5 million as of December 31, 2013. The improvement in shareholders' equity was principally attributable to the increase in net income, conversion of a long term note, and a small private placement in 2013."

"We continue to maintain a successful distribution relationship with Aseptico, which provides us greater transparency with our customers. As a result, we are able to establish a direct relationship with dentists and provide them with a training program through our in-house education staff as well as our hygienists in the field to make an effort to have them use the instrument to the fullest capacity. Due to certain sales incentives and arrangements with our distributors, we anticipate lower handpiece sales in the first quarter and second quarter of 2014 as compared to the fourth quarter of 2013. However, we expect to more than make up for this decline in the second half of 2014 since we know from experience that once we train dentists, they utilize a greater number of handpieces each year. We are also implementing promotions and incentives on the Wand® STA instruments in 2014 to our distributors worldwide which should increase instrument sales. The increase in instrument sales will help drive handpiece sales beginning in the second half of 2014, which will result in increased sales and increased bottom line but lower margins.

"In 2013, we announced a strategic partnership with Tri-anim Health Services Inc., one of the nation's largest specialty distributors of healthcare products. Upon FDA approval, Tri-anim will be the exclusive distributer of Milestone Medical's epidural instrument. Tri-anim is one of the largest distributors to birthing hospitals across the U.S., and is an important validation of the market potential for our instruments."

"Lastly, our subsidiary, Milestone Medical Inc., recently listed on the Warsaw Stock Exchange. The listing followed a $3 million raise from European investors. The money we raised in Poland will help us accelerate the launch of our first two medical instruments, epidural and intra-articular, which are based on our patented Dynamic Pressure Sensing® system. We believe these first two medical instruments represent a significant market opportunity for both Milestone Medical Inc. and Milestone Scientific Inc. We look forward to introducing additional instruments serving a wide array of medical applications, and believe this recent funding demonstrates our ability to cost-effectively bring new instruments to market, while minimizing dilution to shareholders."

Revenue for the three months ended December 31, 2013 increased 23.3% to $2.8 million versus $2.3 million for the fourth quarter of 2012. Domestic instrument sales increased by 30.9% to $378,801 in the fourth quarter of 2013 versus the same quarter in 2012 due to the increased demand at the distributor and group dental practice levels. In the domestic market, handpiece sales increased by $211,547 or 27.3%. On the international front, total revenue was $1,407,455, a 18.9% increase versus the same period in 2012. International handpiece sales increased by $166,973 or 20.6% in the fourth quarter of 2013 versus 2012. Gross profit for the fourth quarter of 2013 was $1.8 million or 65.5% of revenue versus $1.4 million or 59.8% of revenue in the fourth quarter of 2012. Net income for the fourth quarter of 2013 was $1.0 million, or $0.05 per diluted share, versus net loss of ($365,735), or ($0.02) per diluted share for the comparable period in 2012. 

Revenue for the year ended December 31, 2013 increased 15.8% to $10.0 million versus $8.6 million for the year ended 2012. The increase in product sales of $1,363,178 was primarily the result of increased domestic revenue. Domestic instrument sales increased by $377,752 or 44.8% in 2013 versus 2012 due to increased demand at the distributor and group dental practice levels. In the domestic market, handpiece sales increased by $561,355 or 16.5%. International instrument sales increased by $147,517 or 11.3% in 2013 versus 2012. In the international market, handpiece sales increased by $389,434 or 13.2%. Gross profit for 2013 was $6.8 million or 68.0% of revenue versus $5.6 million or 64.7% of revenue in 2012. Operating income for 2013 was $1.1 million versus operating loss of ($520,353) for 2012. Net income for 2013 was $1.5 million or $0.08 per diluted share, versus net loss of ($870,306), or ($0.05) per diluted share in 2012. The increase in net income is attributable to an increase in sales and gross margin dollars, as well as a significant decrease in selling, general and administrative expenses and the net positive impact of Milestone Medical Inc. (joint venture). 

Milestone's executive management team will host a teleconference on Thursday, March 13th at 8:30am Eastern Daylight Time to discuss the company's financial results. The conference call can be accessed via telephone by dialing toll free 1-877-941-9205. For those unable to participate at that time, a replay of the call can be accessed by dialing 1-800-406-7325 and entering the pass code 4673676. The replay will be available for 90 days.

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

                                                                            
                                                                            
                         MILESTONE SCIENTIFIC INC.                          
                     CONDENSED STATEMENTS OF OPERATIONS                     
                                (Unaudited)                                 
                                                                            
                                                                            
                                                                            
                                             December 31,     December 31,  
                                                 2013             2012      
                                           ---------------  --------------- 
Product sales, net                         $    10,011,420  $     8,648,242 
Cost of products sold                            3,198,908        3,055,991 
                                           ---------------  --------------- 
Gross profit                                     6,812,512        5,592,251 
                                           ---------------  --------------- 
Selling, general and administrative                                         
 expenses                                        5,534,463        5,930,625 
Research and development expenses                  191,345          181,979 
                                           ---------------  --------------- 
  Total operating expenses                       5,725,808        6,112,604 
                                           ---------------  --------------- 
    Income (loss) from operations                1,086,704         (520,353)
Other income (expense)                                                      
  Other income                                      17,543                - 
  Interest income                                      115               34 
  Interest expense                                 (70,801)        (175,905)
  Interest-Amortized debt issuance - cost                -           (3,065)
  Loss on Earnings from Medical Joint                                       
   Venture                                        (924,363)        (171,016)
  Loss on Earnings from Education Joint                                     
   Venture                                          (7,918)               - 
  Gain on dilutive effect on Medical Joint                                  
   Venture stock issuance                        1,363,650                - 
                                           ---------------  --------------- 
    Total other expense, net                       378,226         (349,952)
                                           ---------------  --------------- 
      Income (loss)                              1,464,930         (870,306)
                                           ---------------  --------------- 
Provision for Income Tax                                 -                - 
                                           ---------------  --------------- 
      Net income (loss)                    $     1,464,930  $      (870,306)
                                           ===============  =============== 
Net income (loss) per share applicable to                                   
 common stockholders -                                                      
  Basic                                    $          0.09  $         (0.05)
                                           ===============  =============== 
  Diluted                                  $          0.08  $         (0.05)
                                           ===============  =============== 
Weighted average shares outstanding and to                                  
 be issued -                                                                
  Basic                                         17,127,468       16,080,474 
                                           ===============  =============== 
  Diluted                                       17,483,638       16,080,474 
                                           ===============  =============== 
                                                                            
                                                                            
                                                                            
                          MILESTONE SCIENTIFIC INC.                         
                          CONDENSED BALANCE SHEETS                          
                                                                            
                                                                            
                                                                            
                                       December 31, 2013  December 31, 2012 
                                       -----------------  ----------------- 
                                                                            
                ASSETS                                                      
Current Assets:                                                             
  Cash and cash equivalents            $       1,147,198  $         165,249 
  Accounts receivable, net of                                               
   allowance for doubtful accounts of                                       
   $5,000 in 2013 and $179,259 in 2012         1,532,856            978,982 
  Inventories                                  1,321,652            638,561 
  Advances on contracts                          727,478            476,969 
  Prepaid expenses and other current                                        
   assets                                        150,451            239,061 
                                       -----------------  ----------------- 
    Total current assets                       4,879,635          2,498,822 
Accounts receivable-long term, net of                                       
 allowance for doubtful accounts                                            
of $167,971 in 2012                                    -            119,201 
Advances on contracts                          1,580,874          2,350,477 
Investment in Milestone Medical Inc              924,115                  - 
Investment in Milestone Education LLC             42,082                  - 
Furniture, Fixtures & Equipment net of                                      
 accumulated depreciation of                                                
 $476,884as of December 31, 2013 and              23,988             36,624 
 $458,708 as of December 31, 2012                                           
Patents, net of accumulated                                                 
 amortization of $498,502 as of                                             
 December 31, 2013 and $420,556 as of                                       
 December 31, 2012                               591,735            648,662 
Other assets                                      12,917              7,317 
                                       -----------------  ----------------- 
      Total assets                     $       8,055,346  $       5,661,103 
                                       =================  ================= 
                                                                            
 LIABILITIES AND STOCKHOLDERS' EQUITY                                       
Current Liabilities:                                                        
  Accounts payable                     $       2,020,368  $       2,336,594 
  Accrued expenses and other payable             515,132            581,407 
  Accrued interest on Notes Payable                    -            356,563 
                                       -----------------  ----------------- 
    Total current liabilities                  2,535,500          3,274,564 
                                       -----------------  ----------------- 
                                                                            
Long-term Liabilities:                                                      
  Notes payable                                        -            450,000 
                                       -----------------  ----------------- 
    Total long-term liabilities                        -            450,000 
                                       -----------------  ----------------- 
                                                                            
Commitments and Contingencies                                               
                                                                            
Stockholders' Equity                                                        
  Preferred Stock, par value $.001,                                         
   5,000,000 shares                                    -                  - 
  Common stock, par value $.001;                                            
   authorized 50,000,000 shares;                                            
   17,759,540 shares issued 1,839,930                                       
   shares to be issued and 17,726,207                                       
   shares outstanding as of December                                        
   31, 2013; 16,563,306 shares issued                                       
   1,635,709 shares to be issued and                                        
   16,529,973 shares out                          19,599             18,199 
  Additional paid-in capital                  66,677,200         64,560,224 
  Accumulated deficit                        (60,265,438)       (61,730,368)
  Treasury stock, at cost, 33,333                                           
   shares                                       (911,516)          (911,516)
                                       -----------------  ----------------- 
    Total stockholders' equity                 5,519,846          1,936,539 
                                       -----------------  ----------------- 
      Total liabilities and                                                 
       stockholders' equity            $       8,055,346  $       5,661,103 
                                       -----------------  ----------------- 
                                                                            
                                                                            
                                                                            

Investor Relations :
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020  

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
HyperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let's say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: implemen...
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
Most people haven’t heard the word, “gamification,” even though they probably, and perhaps unwittingly, participate in it every day. Gamification is “the process of adding games or game-like elements to something (as a task) so as to encourage participation.” Further, gamification is about bringing game mechanics – rules, constructs, processes, and methods – into the real world in an effort to engage people. In his session at @ThingsExpo, Robert Endo, owner and engagement manager of Intrepid D...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution. In his session at @ThingsExpo, Akvelon expert and IoT industry leader Sergey Grebnov provided an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.